RxDoctor Payments Data

Melody Evans

Family Medicine · Okmulgee, OKNPI 1811571110

Payments from drug & device makers

$1,498in general payments, 2019–2025

Across 77 payments — averaging $19.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$351
  • Novo Nordisk$189
  • AbbVie$159
  • Lundbeck LLC$129
  • Acadia Pharmaceuticals Inc$117
  • AstraZeneca$75
  • plus $477 from 16 others

What the payments were for

  • Food & beverage$1,498100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,498 in reported general payments places this provider in the 65th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$40,508
Medicare patients
83
Services billed
780

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide164$165,411
MounjaroTirzepatide90$92,766
EliquisApixaban58$76,086
Dupixent PenDupilumab20$73,478
JanuviaSitagliptin Phosphate62$53,657
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$33,441
TrulicityDulaglutide35$33,330
ProliaDenosumab19$32,809
RexultiBrexpiprazole14$21,478
XareltoRivaroxaban15$18,891
FarxigaDapagliflozin Propanediol14$18,541
EntrestoSacubitril/Valsartan18$16,635
JardianceEmpagliflozin16$15,200
GemtesaVibegron19$13,738
Combivent RespimatIpratropium/Albuterol Sulfate15$11,372

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$189$165,411164 claims
Lilly USA, LLCMounjaro, Trulicity$53$126,096125 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$12$44,77979 claims
AstraZenecaFarxiga, Symbicort$75$21,85530 claims
Otsuka America Pharmaceutical, Inc.Rexulti$351$21,47814 claims
NovartisEntresto$34$16,63518 claims
AbbVieLinzess$159$10,72713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Okmulgee

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →